Who we are and what we do
GSK.ca
Our news
NUCALA (mepolizumab) approved in Canada as the first and only biologic treatment for adults with hypereosinophilic syndrome
GSK receives authorization under Health Canada’s Interim Order for Sotrovimab for Injection to treat COVID-19 in high-risk adults and adolescents
BENLYSTA now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients
Transparency reporting
At GSK, we’re committed to building transparency as we believe it enhances trust for patients and our healthcare system. Since 2017, GSK has voluntarily disclosed in aggregate payments to Healthcare Professionals (HCPs) and payments to Healthcare Organizations (HCOs). Starting this year, we are expanding the reporting to include payments to individual HCPs. You can view our transparency reporting here.
Learn more about transparency reporting
Explore our products
We make a wide range of prescription medicines, prescribed vaccines and consumer healthcare products.
Working at GSK
Looking for a new career? Find out about working at GSK and how to apply for a job.
